Auris Medical
Cochlear therapies

Innovative Treatments for Inner Ear Disorders

Business Update & Financial Results

Full Year 2016

March 14, 2017

Forward-looking Statements

Auris Medical
Cochlear therapies

This presentation and the accompanying oral commentary contain “forward-looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary, including statements regarding our future financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “might,” “approximately,” “expect,” “predict,” “could,” “potentially” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places throughout this presentation and the accompanying oral commentary and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates AM-101 and AM-111, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These include, but are not limited to, the timing and conduct of clinical trials of our product candidates, the clinical utility of our product candidates, including the likelihood that the TACTT3 trial may not meet its endpoints, the timing or likelihood of regulatory filings and approvals, the timing or likelihood of regulatory filings and approvals, our intellectual property position and our financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to our capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in our Annual Report on Form 20-F and future filings with the Securities and Exchange Commission. Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Recent Developments Strengthen Pipeline

Auris Medical
Cochlear therapies

- **AM-111** — Received Fast Track designation from FDA
- **Keyzilen®** — Resumed enrollment in TACTT3
- **AM-125** — Addition of third clinical-stage program

Expanded Pipeline of Product Candidates

Auris Medical
Cochlear therapies

Product	Indication	Preclin.	Phase 1	Phase 2	Phase 3	Next Key Milestones	
Keyzilen® (AM-101) Esketamine	*Acute inner ear tinnitus*					Data TACTT3 (A)	Q1 2018
	Post-acute inner ear tinnitus					Data TACTT3 (B)	Q1 2018
	Repeated dose safety					Data AMPACT1	Q2 2017
	Repeated dose safety					Data AMPACT2	Q2 2017
AM-111 Brimapitide/ D-JNKI-1	*ASNHL (sudden deafness)*					Data HEALOS	Q3 2017
	ASNHL (sudden deafness)					Data ASSENT	2H 2018
AM-125 Betahistine	*Meniere's disease & Vestibular vertigo*					Initiate second Phase 1	2H 2017
AM-102 Undisclosed	*Tinnitus*					Select lead compound	Q4 2017
AM-123 Undisclosed	*Rhinology*					Select lead compound	Q4 2017

AM-111: Upcoming Phase 3 Data

- Potential to become first therapeutic indicated specifically for treatment of acute inner ear hearing loss
- Fast track and orphan drug designation
- Two Phase 3 trials ongoing:
  - HEALOS: Expect top-line results in 3Q17
  - ASSENT: Expect top-line results in 2H18

Keyzilen: TACTT3 Phase 3 Trial Ongoing

- Fast track designation for treatment of acute inner ear tinnitus
- TACTT3 trial ongoing with top-line results expected in 1Q18
  - Implemented three protocol amendments:
    1. Elevated TFI to alternate primary endpoint from key secondary endpoint
    2. Including subgroups of patients with tinnitus following otitis media and those with severe or extreme tinnitus at baseline in confirmatory testing
    3. Enrolling 60 additional patients in each of Stratum A and B
- Results from open-label extension studies, AMPACT 1 & 2, expected in 2Q17
  - Evaluating long-term safety of Keyzilen

AM-125: Intranasal Delivery of Betahistine

- Pursuing novel, intranasal administration of betahistine for treatment of Meniere's disease and vestibular vertigo
  - Seek to improve efficacy by avoiding strong first-pass effect of oral dosing
- Initial Phase 1 results demonstrated good tolerance and dose-dependent increase in betahistine plasma concentrations
  - Significantly higher than reported with oral administration
- Preparing for regulatory discussions and assembling advisory board
- Plan to initiate second Phase 1 trial this year

Full Year 2016 Financial Update

- Net loss for 2016 was CHF 30.7 million, or CHF 0.89, compared to CHF 29.7 million, or CHF 0.92, in 2015
- Research and development expenses decreased from CHF 26.5 million in 2015 to CHF 24.8 million in 2016
- General and administrative expenses increased from CHF 4.3 million in 2015 to CHF 5.4 million in 2016
- Cash and cash equivalents as of December 31, 2016, totaled CHF 32.4 million
  - Does not include net proceeds of $9.1 million from February 2017 offering
- 2016 operating expense guidance remains CHF 28 to 32 million
- Cash runway extended into the first quarter of 2018

Annual General Meeting

Annual General Meeting

April 13, 2017

Zug, Switzerland

Meeting agenda available at www.aurismedical.com

Mats Blom

Proposed member of Board of Directors

- *CFO of Zealand Pharma*
- *Previously served as CFO of Swedish Orphan International, Active Biotech and Anoto Group*

Key Upcoming Milestones

Second Quarter 2017	• Complete enrollment of HEALOS
Second Quarter 2017	• Announce AMPACT open-label trial results
Third Quarter 2017	• Complete enrollment of TACTT3
Third Quarter 2017	• Announce HEALOS top-line results
Second Half 2017	• Initiate AM-125 Phase 1 trial

Questions & Answers

Auris Medical
Cochlear therapies



Take care of your ears!

Investor Relations Contact: Cindy McGee
investors@aurismedical.com

Auris Medical Holding AG
Bahnhofstrasse 21
CH-6300 Zug
Tel. +41 41 729 71 94 | Fax +41 61 201 13 51
www.aurismedical.com | NASDAQ: EARS

Auris Medical
Cochlear therapies